Alizadegan, F.2024-09-122024-09-122022-10-200181-5512https://doi.org/10.1016/j.jfo.2022.04.009https://hdl.handle.net/11452/44629Purpose. - To evaluate the efficacy of infliximab (IFX) therapy in patients with Behc , et's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).Materials and methods. - This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic char-acteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Results. - Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 +/- 25.9 months. The mean frequency of recurrences during the IMT was 1.47 +/- 0.78 (attacks/year), decreasing to 0.31 +/- 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases.Conclusion. - IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.eninfo:eu-repo/semantics/closedAccessNecrosis-factor-alphaRefractory uveoretinitisFollow-upDiseaseCytokinesInductionRemissionAnti tumor necrosis factorBehcet&rsquoS diseaseInfliximabNoninfectiousUveitisScience & technologyLife sciences & biomedicineOphthalmologyArticle0008776844000231036104145910.1016/j.jfo.2022.04.009